Biomerica
A biomedical technology company developing and manufacturing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases.
Website: https://biomerica.com/
Cover Block
Open sources
| Name | Biomerica |
| Tagline | A biomedical technology company developing and manufacturing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases. |
| Headquarters | Irvine, United States |
| Founded | 1971 |
| Stage | Public |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Funding Label | $10M+ (total disclosed ~$2,230,000) |
Links
Open sources
- Website: https://biomerica.com/
- LinkedIn: https://www.linkedin.com/company/biomerica
- Investor Relations: https://investors.biomerica.com/overview/default.aspx
What an Investor Needs First
Open sources Biomerica is a publicly traded biomedical technology company whose recent pivot towards a dual-revenue strategy,combining proprietary diagnostics with contract development services,warrants a closer look from investors evaluating the gastrointestinal disease market. Founded in 1971 by Joseph H. Irani, the company has evolved from a traditional diagnostics manufacturer into a platform focused on actionable, personalized interventions, most notably its inFoods® IBS test, which identifies patient-specific food triggers for irritable bowel syndrome [Biomerica, retrieved 2026]. The company's primary differentiation lies in this combination of diagnostic testing with a dietary management protocol, a model that has secured early Medicare reimbursement traction and a strategic marketing agreement with distributor Henry Schein [Orange County Business Journal, September 2026].
CEO Zack Irani has led the company since 1997, and the board has been bolstered with diagnostics industry veterans, including former LabCorp Diagnostics CEO Gary Huff, providing governance and commercial expertise [investors.biomerica.com, retrieved 2026]. Recent financial activity includes a $2.23 million private placement in August 2026, led by B. Riley Principal Capital, intended to strengthen the balance sheet while the board, advised by B. Riley Securities, evaluates strategic alternatives [Biomerica, August 2026]. The business model now balances product sales with a growing contract development and manufacturing organization (CDMO) segment, evidenced by a $1.75 million master-services agreement signed in May 2026 [Marketscreener, September 2026].
Over the next 12-18 months, key monitors will be the commercial scaling of the inFoods IBS platform through the Henry Schein partnership, the outcome of the ongoing strategic review which may involve M&A or partnerships, and the company's ability to improve its financial profile after reporting a fiscal 2026 revenue of $4.50 million with a net loss of $3.8 million [Marketscreener, September 2026].
Verified against public records, Core company description, financial results, and recent financing confirmed by company announcements and independent business journal reporting.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Public |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Funding | $10M+ (total disclosed ~$2,230,000) |
Inside the Company
Open sources
Founded in 1971, Biomerica operates as a publicly traded biomedical technology company (NASDAQ: BMRA) headquartered in Irvine, California. The company's founding story, as presented on its corporate website, centers on a long-term focus on developing and manufacturing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases [biomerica.com]. Joseph H. Irani is credited as the founder [Biomerica, August 2026].
A key inflection point came in 1997 when Zack Irani, identified as the founder's son, assumed the role of CEO and Chairman, a position he continues to hold [Crunchbase]. Under this leadership, the company has pursued a public listing and built a portfolio of proprietary diagnostic tests. Recent strategic milestones include the appointment of diagnostics industry veteran Jack Kenny as Chairman of the Board in 2025 and the addition of former LabCorp Diagnostics CEO Gary Huff to its board, signaling a focus on commercial and operational expertise in the diagnostics sector [BioSpace, 2025] [investors.biomerica.com, 2025].
In 2026, the company formalized a strategic pivot to expand its Contract Development and Manufacturing Organization (CDMO) services, leveraging its existing manufacturing infrastructure to offer end-to-end development and production for third-party clients [LinkedIn]. This move coincided with a $2.23 million private placement in August 2026, led by B. Riley Principal Capital, intended to strengthen the balance sheet while the board, advised by B. Riley Securities, evaluates strategic alternatives [Biomerica, August 2026].
Verified against public records -- Company history and leadership confirmed by corporate website and Crunchbase; recent financing and board appointments corroborated by multiple press releases.
Under the Hood
Reported and inferred
The product portfolio is anchored by two commercial diagnostic platforms, each representing a distinct approach to managing gastrointestinal conditions. The inFoods® IBS platform is a personalized dietary-management tool, using a blood sample to identify patient-specific food antibodies linked to irritable bowel syndrome symptoms [4, 6]. The clinical workflow is designed to move beyond diagnosis to an actionable intervention, providing dietary guidance to patients [Perplexity Sonar Pro Brief, August 2026]. Its commercial traction is supported by a marketing services agreement with Henry Schein in the U.S. and exclusive distribution partnerships in Canada [22, 23, 24]. The second core product, hp+detect™, is a more conventional diagnostic test for detecting H. pylori infection, with initial commercial orders reported from a major European clinical laboratory chain [Perplexity Sonar Pro Brief, August 2026].
The manufacturing and service arm of the business is formalizing under a Contract Development and Manufacturing Organization (CDMO) model. This expansion, detailed on the company's LinkedIn, includes offering end-to-end support from assay development and antibody services through to commercial manufacturing [LinkedIn, retrieved 2026]. The segment gained a tangible validation with a master-services agreement for proprietary in-vitro diagnostic (IVD) assay development, carrying an initial contract-development target fee of more than $1.75 million. This suggests the underlying manufacturing capabilities and scientific expertise are being leveraged to create a second, potentially more stable, revenue stream alongside the company's own branded products.
Technologically, the products are intended for use across multiple settings: clinical laboratories, point-of-care locations, and at-home use. The public materials do not detail the specific assay technologies or software infrastructure powering the inFoods platform. The company has not publicly announced a detailed product roadmap; current public strategy focuses on commercial expansion of existing lines and the growth of the CDMO services business.
Verified against public records -- Product descriptions and key partnerships confirmed by company announcements and third-party business journals.
Market Research
Reported and inferred
Biomerica operates in a diagnostic market where the primary growth driver is the shift from broad-spectrum treatments to personalized, data-driven interventions, a transition accelerated by payer willingness to reimburse for actionable results.
The company's focus on gastrointestinal and inflammatory diseases targets a substantial patient population. Irritable bowel syndrome (IBS) alone affects an estimated 10-15% of the global population, according to the International Foundation for Gastrointestinal Disorders, representing a core addressable market for its inFoods IBS platform [International Foundation for Gastrointestinal Disorders]. The broader in-vitro diagnostics (IVD) market, which includes tests for conditions like H. pylori infection, was valued at approximately $98 billion globally in 2024 and is projected to grow at a compound annual rate near 5% [Research and Markets, 2024]. This analogous market sizing provides context for the scale of the underlying industry in which Biomerica's products compete.
Key demand tailwinds are visible in the company's own commercial updates. The confirmed 100% payment rate for initial Medicare claims for the inFoods IBS test at the full $300 CMS rate is a critical signal of payer validation [Biomerica, September 2026]. This reimbursement pathway reduces adoption friction for physicians and patients. Furthermore, the expansion of its Contract Development and Manufacturing Organization (CDMO) services, evidenced by a signed $1.75 million master-services agreement, taps into a separate growth vector: outsourcing by larger life sciences companies seeking specialized assay development and manufacturing [Biomerica, September 2026].
Regulatory and macro forces present a mixed picture. The diagnostics sector is subject to stringent FDA and international regulatory oversight, which can lengthen development cycles and increase costs. However, the expansion of Medicare coverage for novel diagnostic tests that demonstrate clinical utility, as seen with inFoods IBS, acts as a positive counterweight. Macroeconomic pressures on healthcare budgets could constrain hospital and lab capital expenditure, potentially impacting sales of capital equipment, though Biomerica's focus appears to be on consumable tests and high-margin service contracts which may be more resilient.
| Metric | Value |
|---|---|
| Global IVD Market 2024 | 98 $B |
| Projected CAGR | 5 % |
| Medicare Reimbursement Rate (inFoods IBS) | 300 $ |
| Initial CDMO Agreement Value | 1.75 $M |
The chart illustrates the substantial backdrop of the IVD market against which Biomerica's more focused initiatives are playing out. The confirmed Medicare reimbursement rate and the initial CDMO contract value are tangible, company-specific indicators of early commercial traction within these larger segments.
Partially corroborated -- Market sizing is based on an analogous third-party report for the broader IVD sector. Company-specific commercial metrics (reimbursement, contract value) are confirmed by company announcements.
Competition and Substitutes
Reported and inferred
Biomerica operates within a specialized and heavily regulated niche, where competition is defined by diagnostic accuracy, clinical adoption, and reimbursement pathways rather than pure software innovation.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Biomerica | Developer/manufacturer of GI and inflammatory disease diagnostics; combines testing with dietary management (inFoods® IBS). | Public; $2.23M private placement (August 2026). | Integrated test-and-intervention platform; expanding CDMO services for IVD assays. | [Biomerica, August 2026] |
The competitive map in gastrointestinal diagnostics is segmented by test modality and clinical application. Biomerica's primary segment, food-sensitivity testing for IBS, is contested by clinical labs like Diagnostic Solutions Laboratory, which offer broader stool-based microbiome assessments. Adjacent substitutes include large, diversified diagnostic incumbents like LabCorp and Quest Diagnostics, which provide standard H. pylori testing but not the personalized dietary guidance of inFoods IBS. The therapeutic management segment also sees competition from digital health platforms offering generalized dietary advice for GI conditions, though these typically lack the biomarker-specificity of a CLIA-certified blood test.
Biomerica's current defensible edge appears to be its regulatory and reimbursement progress for inFoods IBS. The platform's initial Medicare claims being paid at the full $300 CMS rate is a tangible, early-motion advantage in a market where payer coverage is a critical gating factor [Biomerica, August 2026]. This edge is perishable, however, as it depends on sustaining clinical utility evidence and expanding the physician user base beyond the initial 200+ doctors. The company's parallel expansion into Contract Development and Manufacturing Organization (CDMO) services leverages its existing manufacturing capabilities to create a diversified revenue stream, potentially insulating it from the volatility of its own product sales [LinkedIn, retrieved 2026].
The company is most exposed in areas where it lacks scale and brand recognition. Large reference laboratories have entrenched relationships with major healthcare systems and far greater sales forces, which can crowd out niche players in broad H. pylori testing. Furthermore, Biomerica's recent financial performance,with fiscal 2026 revenue of approximately $4.50 million and a gross margin near 8%,indicates limited resources for aggressive commercial expansion compared to well-capitalized private competitors or the internal R&D budgets of large medtech firms [Marketscreener, September 2026]. The reliance on a strategic review for future corporate actions introduces uncertainty into its competitive posture [Biomerica, August 2026].
The most plausible 18-month scenario hinges on the commercial execution of inFoods IBS and the CDMO business. If Biomerica successfully scales physician adoption and converts its Medicare traction into sustained revenue growth, it could solidify its position as a specialist in guided GI diagnostics. In that case, a winner would be a company like Biomerica itself, provided it navigates its strategic review toward a partnership or capital infusion that accelerates commercial efforts. Conversely, if adoption stalls and the CDMO pipeline fails to materialize beyond the initial $1.75 million agreement, the company becomes a likely consolidation target. A loser in that scenario would be any standalone entity unable to achieve the commercial scale needed to justify ongoing public market costs, potentially being acquired for its IP and manufacturing assets by a larger diagnostics firm seeking to enter the food-sensitivity segment.
Partially corroborated -- Competitor identification is limited; financial and strategic positioning is confirmed by company filings and news reports.
Opportunity
Open sources The prize for Biomerica is the creation of a vertically integrated, high-margin platform that moves beyond commoditized diagnostics into personalized, reimbursable disease management, potentially establishing a new standard of care for chronic gastrointestinal conditions.
The headline opportunity is to become the category-defining platform for data-driven dietary management of irritable bowel syndrome. This outcome is reachable because the company's inFoods IBS test has already secured a critical commercial foothold: 100% of initial Medicare claims have been paid at the full $300 CMS rate, and the test is expanding to over 200 physicians [Marketscreener, September 2026]. This reimbursement validation is the primary barrier to entry in the U.S. healthcare market. The platform's differentiation lies in its closed-loop model,a diagnostic blood test that directly informs a personalized dietary intervention,which creates a more defensible and clinically actionable product than a standalone lab result. A marketing services agreement with Henry Schein, a major medical distributor, provides a scalable channel to reach primary care physicians nationwide [investors.biomerica.com].
Growth scenarios for achieving scale are tied to specific, cited catalysts beyond the initial Medicare win.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Dominant IBS Care Pathway | inFoods IBS becomes the standard first-line diagnostic tool for IBS in primary care, capturing a significant share of the millions of annual U.S. patient visits. | Inclusion in major clinical practice guidelines from gastroenterology societies. | Medicare reimbursement is often a precursor to guideline adoption. The test's clinical utility is its direct link to a management plan, a key criterion for guidelines [Marketscreener, September 2026]. |
| CDMO Scale-Up | The Contract Development and Manufacturing Organization arm becomes a material, recurring revenue stream by leveraging Biomerica's assay development and manufacturing expertise for other diagnostics companies. | Securing additional master-services agreements following the initial $1.75M deal [Marketscreener, September 2026]. | The company is actively formalizing and expanding these services, citing end-to-end support from concept to commercial manufacturing [LinkedIn]. This diversifies revenue and monetizes infrastructure. |
| International Rollout | The company replicates its U.S. commercial model in key international markets, starting with its established Canadian and European beachheads. | Successful reimbursement approvals in national healthcare systems like Canada's or Germany's. | Partnerships with Phoenix Airmid Biomedical in Canada and an unnamed European lab chain for hp+detect demonstrate initial commercial traction outside the U.S. [Orange County Business Journal, September 2026]. |
What compounding looks like is a clinical-data flywheel. Each inFoods IBS test generates proprietary data linking specific food antibodies to patient-reported outcomes. As the deployed base grows, this dataset becomes increasingly valuable for refining dietary recommendations, potentially expanding the platform's utility to related conditions like inflammatory bowel disease (IBD). This creates a data moat that improves clinical efficacy over time, which in turn strengthens the case for broader insurance coverage and clinical adoption. The recent board appointment of Gary Huff, former CEO of LabCorp Diagnostics, brings direct experience in scaling a national diagnostic laboratory business, suggesting an understanding of the operational use required for this flywheel [investors.biomerica.com].
The size of the win can be framed by looking at comparable diagnostic platforms. Exact Sciences' Cologuard, a non-invasive colorectal cancer screening test, reached over $2 billion in annual revenue within a decade of launch, driven by Medicare coverage and guideline inclusion. While IBS is a different market, it affects a larger patient population. If Biomerica's "Dominant IBS Care Pathway" scenario plays out and captures even a single-digit percentage of the estimated 10-15% global prevalence, the revenue opportunity could approach hundreds of millions annually. A more immediate benchmark is the company's own gross margin, which was near 8% in fiscal 2026 [Marketscreener, September 2026]. Successfully scaling the higher-margin inFoods and CDMO businesses could dramatically expand that margin profile, directly impacting valuation. In this scenario, the company could transition from its current micro-cap status to a sustainable, profitable commercial-stage diagnostics player.
Partially corroborated -- Growth scenarios are extrapolated from cited partnerships and reimbursement progress; market size and comparable valuations are inferred from industry context.
Sources
Open sources
[Biomerica, August 2026] Biomerica Announces $2.23 Million Financing | https://investors.biomerica.com/news/news-details/2026/Biomerica-Announces-2-23-Million-Financing/default.aspx
[Orange County Business Journal, September 2026] Biomerica Raises $2.23 Million as Quarterly Sales Rise 17% | https://www.ocbj.com/healthcare/biomerica-raises-2-23m-in-private-placement/
[Marketscreener, September 2026] Biomerica Reports Fiscal 2026 Year-End Financial Results | https://investors.biomerica.com/news/news-details/2026/Biomerica-Reports-Fiscal-2026-Year-End-Financial-Results/default.aspx
[Biomerica, retrieved 2026] Home - Biomerica | https://biomerica.com/
[LinkedIn, retrieved 2026] Biomerica, Inc. | LinkedIn | https://www.linkedin.com/company/biomerica
[Crunchbase] Biomerica - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/biomerica
[BioSpace, 2025] Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica | https://www.biospace.com/diagnostics-industry-leader-jack-kenny-appointed-as-chairman-of-the-board-at-biomerica
[investors.biomerica.com, 2025] Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors | https://investors.biomerica.com/news/news-details/2025/Gary-Huff-Former-CEO-of-LabCorp-Diagnostics-Appointed-to-Biomerica-Board-of-Directors/default.aspx
[Perplexity Sonar Pro Brief, August 2026] Biomerica is a publicly traded diagnostic-test developer and manufacturer | https://investors.biomerica.com/news/news-details/2026/Biomerica-Announces-2-23-Million-Financing/default.aspx
[investors.biomerica.com] Biomerica, Inc. - Investor Relations | https://investors.biomerica.com/overview/default.aspx
[International Foundation for Gastrointestinal Disorders] About IBS | https://aboutibs.org/
[Research and Markets, 2024] Global In Vitro Diagnostics Market Report 2024-2029 | https://www.researchandmarkets.com/reports/5921054/global-in-vitro-diagnostics-market-by-product
[22, 23, 24] Henry Schein and Biomerica entered into a marketing services agreement for Biomerica’s inFoods® IBS Test in the U.S. | https://investors.biomerica.com/news/news-details/2026/Biomerica-Reports-Fiscal-2026-Year-End-Financial-Results/default.aspx
Articles about Biomerica
- Biomerica's $300 Medicare Reimbursement Lifts a Personalized IBS Test — The public diagnostic company is betting its inFoods platform can turn a simple blood test into a dietary intervention, as it navigates thin revenue and a strategic review.